Gene delivery for cerebral neurodegenerative disorders - current advancements and limitations.
Gene therapy for brain degeneration advances through improved vector design and blood-brain barrier techniques, though clinical translation remains in early stages.
This review of CNS gene delivery for neurodegenerative disorders surveys in vivo and ex vivo strategies spanning AAV vectors, ASOs, and nanoparticles, highlighting barriers including the blood-brain barrier, pre-existing immunity to viral capsids, and dose-limiting toxicities. The paper situates ML-guided capsid design and controllable BBB modulation as key future advances, but the field remains at an early clinical translation stage for most indications.
What the study was
- Study design
- Narrative review
- Category
- Drug Development
- Maturity
- Exploratory
- Journal
- Molecular Therapy
Why it surfaced
Peripheral watchlist match (T4 via AI-guided capsid design mention); primary focus is neurodegenerative gene therapy, which is a broader unmet-need area but not core watchlist scope.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.